Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.69
AMRN's Cash to Debt is ranked higher than
58% of the 774 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. AMRN: 0.69 )
AMRN' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.69

Equity to Asset -0.24
AMRN's Equity to Asset is ranked lower than
58% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. AMRN: -0.24 )
AMRN' s 10-Year Equity to Asset Range
Min: -0.82   Max: 0.83
Current: -0.24

-0.82
0.83
F-Score: 4
Z-Score: -6.12
M-Score: 0.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -691.08
AMRN's Operating margin (%) is ranked lower than
57% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.25 vs. AMRN: -691.08 )
AMRN' s 10-Year Operating margin (%) Range
Min: -6232.2   Max: -9.44
Current: -691.08

-6232.2
-9.44
Net-margin (%) -630.82
AMRN's Net-margin (%) is ranked lower than
56% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. AMRN: -630.82 )
AMRN' s 10-Year Net-margin (%) Range
Min: -5384   Max: 394.49
Current: -630.82

-5384
394.49
ROA (%) -65.84
AMRN's ROA (%) is ranked lower than
55% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.09 vs. AMRN: -65.84 )
AMRN' s 10-Year ROA (%) Range
Min: -705.71   Max: 16.91
Current: -65.84

-705.71
16.91
ROC (Joel Greenblatt) (%) -31451.81
AMRN's ROC (Joel Greenblatt) (%) is ranked lower than
58% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.47 vs. AMRN: -31451.81 )
AMRN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -51251.14   Max: -13.01
Current: -31451.81

-51251.14
-13.01
EBITDA Growth (%) -31.50
AMRN's EBITDA Growth (%) is ranked higher than
51% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. AMRN: -31.50 )
AMRN' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 85.5
Current: -31.5

0
85.5
EPS Growth (%) -25.50
AMRN's EPS Growth (%) is ranked higher than
57% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. AMRN: -25.50 )
AMRN' s 10-Year EPS Growth (%) Range
Min: -77.8   Max: 155.7
Current: -25.5

-77.8
155.7
» AMRN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

AMRN Guru Trades in Q3 2013

Louis Moore Bacon 300,000 sh (+275%)
Steven Cohen 1,000,000 sh (unchged)
Pioneer Investments 270,000 sh (unchged)
Steven Cohen 655,024 sh (-42.71%)
» More
Q4 2013

AMRN Guru Trades in Q4 2013

Paul Tudor Jones 31,015 sh (New)
Pioneer Investments 270,000 sh (unchged)
Steven Cohen 1,000,000 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
» More
Q1 2014

AMRN Guru Trades in Q1 2014

Steven Cohen 610,313 sh (New)
Pioneer Investments 270,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2014

AMRN Guru Trades in Q2 2014

Jim Simons 184,200 sh (New)
Pioneer Investments 270,000 sh (unchged)
Steven Cohen 1,361,832 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-03-31 Sold Out 0.08%$6.965 - $9.16 $ 1.83-78%0
John Burbank 2012-12-31 New Buy0.08%$7.68 - $12.6 $ 1.83-83%250000
George Soros 2012-09-30 Sold Out 0.06%$11.17 - $15.49 $ 1.83-86%0
George Soros 2012-06-30 New Buy0.06%$9.47 - $14.74 $ 1.83-84%300000
George Soros 2011-09-30 Sold Out 0.058%$8.95 - $14.82 $ 1.83-85%0
George Soros 2011-06-30 Reduce -56.15%0.04%$7.39 - $19.5 $ 1.83-88%285000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 8.20
AMRN's P/S is ranked lower than
66% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.45 vs. AMRN: 8.20 )
AMRN' s 10-Year P/S Range
Min: 0.24   Max: 930
Current: 8.2

0.24
930
EV-to-EBIT -3.14
AMRN's EV-to-EBIT is ranked higher than
56% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.72 vs. AMRN: -3.14 )
AMRN' s 10-Year EV-to-EBIT Range
Min: 12.7   Max: 22.8
Current: -3.14

12.7
22.8
Current Ratio 4.69
AMRN's Current Ratio is ranked higher than
84% of the 560 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. AMRN: 4.69 )
AMRN' s 10-Year Current Ratio Range
Min: 0.27   Max: 35.14
Current: 4.69

0.27
35.14
Quick Ratio 4.24
AMRN's Quick Ratio is ranked higher than
84% of the 560 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.77 vs. AMRN: 4.24 )
AMRN' s 10-Year Quick Ratio Range
Min: 0.22   Max: 35.14
Current: 4.24

0.22
35.14

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.10
AMRN's Price/Median PS Value is ranked higher than
99% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. AMRN: 0.10 )
AMRN' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 10.44
Current: 0.1

0.01
10.44
Forward Rate of Return (Yacktman) -100.75
AMRN's Forward Rate of Return (Yacktman) is ranked lower than
54% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. AMRN: -100.75 )
AMRN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -50   Max: -27.9
Current: -100.75

-50
-27.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:EH3A.Germany
Amarin Corporation PLC formerly Ethical Holdings plc is a public limited company incorporated under the laws of England and Wales. It was originally incorporated in England as a private limited company on March 1, 1989 under the Companies Act 1985, and re-registered in England as a public limited company on March 19, 1993. The Company is a biopharmaceutical company that commercializes and develops therapeutics to improve cardiovascular health. On July 26, 2012, it received approval from the U.S. Food and Drug Administration, or FDA, to market and sell its product Vascepa (icosapent ethyl) capsules (formerly known as AMR101) as an adjunct to diet to reduce triglyceride, or TG, levels in adult patients with severe (TG500mg/dL) hypertriglyceridemia, which it sometimes refers to as the MARINE indication. Vascepa became commercially available in the United States by prescription in January 2013, when it commenced sales and shipments to their network of U.S.-based wholesalers. On January 28, 2013, it commenced full commercial launch of Vascepa in the United States for the MARINE indication. The Company is also developing Vascepa for the treatment of patients with high (TG  200 mg/dL and <500 mg/dL) triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol, or LDL-C, levels which it refers to as mixed dyslipidemia. The biotechnology and pharmaceutical industries are highly competitive. There are many pharmaceutical companies, biotechnology companies, public and private universities and research organizations actively engaged in the research and development of products that may be similar to its products. The Company 's potential competitors both in the United States and Europe include large, well-established pharmaceutical companies, specialty pharmaceutical sales and marketing companies and specialized cardiovascular treatment companies. Any product development activities related to Vascepa or products that it may develop or acquire in the future will be subject to extensive regulation by various government authorities, including the FDA and comparable regulatory authorities in other countries, which regulate the design, research, clinical and non-clinical development, testing, manufacturing, storage, distribution, import, export, labeling, advertising and marketing of pharmaceutical products and devices.
» More Articles for NAS:AMRN

Headlines

Articles On GuruFocus.com
Morning Coffee: Widely Held International Guru Stocks Near 52-Week Lows May 23 2014 
Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN Jan 07 2013 
Steven Cohen Adds Amarin Corp. Awaiting Drug Approval, Buys Hyatt Hotels Mar 28 2012 
Soros Funds’ Great Britain Buys and Sells Apr 13 2011 

More From Other Websites
AMARIN CORP PLC\UK Financials Aug 15 2014
Amarin Reports Second Quarter 2014 Financial Results and Provides Update on Operations Aug 07 2014
AMARIN CORP PLC\UK Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 07 2014
Amarin Reports Second Quarter 2014 Financial Results and Provides Update on Operations Aug 07 2014
Amarin to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, August 7,... Aug 07 2014
Amarin to Report Second Quarter 2014 Results and Host Conference Call on August 7, 2014 Aug 05 2014
Amarin to Report Second Quarter 2014 Results and Host Conference Call on August 7, 2014 Aug 05 2014
Amarin Moves Higher On Speculation Of Special Protocol Assessment Jul 31 2014
Amarin Shocker: There's a Reason to be Bullish Right Now Jul 31 2014
Amarin: Will The Lamb Of Ireland Bleat Or The Lion Of The People Roar? Jul 21 2014
AMARIN CORP PLC\UK Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 10 2014
Amarin Scrapes The Bottom Of The Barrel Jun 27 2014
Rick Harrison of Television's "Pawn Stars®" Discusses His Revelations on Seeking Treatment for His... Jun 25 2014
Update-Moody's downgrades Novasep's probability of default rating to Caa1-PD from B3-PD; outlook... Jun 13 2014
Stagnant Sales An Ominous Sign For Amarin Jun 12 2014
Amarin announces Vascepa case study publication Jun 11 2014
Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid... Jun 11 2014
Amarin to Present at the Goldman Sachs 2014 Global Healthcare Conference Jun 04 2014
Amarin to Present at the Jefferies 2014 Global Healthcare Conference May 29 2014
AMARIN CORP PLC\UK Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... May 21 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide